RAPT Therapeutics, Inc. RAPT
Set alert
As of Mar 6, 9:30 AM ET
- YTD
- +71.26%
- 1 year
- +547.38%
- Open
- 58.01
- Prev close
- 58.01
- Mkt cap
- 1.61B
- Vol
- 10.85M
- Avg vol
- 4.25M
- EPS
- -11.06
- P/E
- -44.46
- Div yield
- 0.00%
More statistics
- Low
- 58.01
- High
- 58.01
- Beta
- 0.44
- Inst. own
- 110.57%
- Dividend
- 0.00
Discussion (9)
Sign in to join the discussion
Buying more here from weak hands
Now i can say, i said so. This will hold around $3
$RAPT Patience is the key. It still has around 86% of institutional holdings that should give you the confidence of bouncing back when study is completed in jan 2025
$RAPT, i belive tgere will be a positivd news in Jan when full stufy will be completed. Check https://www.clinicaltrials.gov/study/NCT03674567?term=flx475&rank=3
I belive FLX475 (tivumecirnon is a success, it just has to go through the process. Lots of articles have been published supporting it. Here is one for you https://www.biospace.com/rapt-therapeutics-announces-positive-data-including-objective-response-rates-and-progression-free-survival-from-its-phase-2-trial-of-flx475-in-combination-with-a-checkpoint-inhibitor-in-patients-with-advanced-nsclc
Price target of $3 upside of 230% from here
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer Study Start (Actual)
2018-09-25
Primary Completion (Estimated)
2024-09
Study Completion (Estimated)
2025-01
Enrollment (Actual)
323
$RAPT Oversold will reverse today